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Summary
Forty-two patients in the acute phase of onyalai
were admitted to hospital and randomly divided into
three groups of 14 to receive prednisolone 3 mg/kg/d
for 1 week, intravenous gammaglobulin 100 mg/kg
on 2 successive days, or ascorbic acid 1 000 mg
3 times a day for 1 week. The groups were comparable
with regard to sex and age distribution, initial platelet
c.ounts and initial haemoglobin values. No statistical
difference was observed between the three treatment
groups with regard to changes in the platelet counts
during the period of observation. One patient died
from haemorrhagic shock. The low mortality rate in
this series suggests that admission to' hospital and
early. correction of blood loss are important factors
in reducing the mortality rate associated with onyalai.
S Air Med J 1984; 66: 917-918.
The objective of this prospective therapeutic trial was to
compare the short-term effects of prednisolone, intravenous
gammaglobulin and placebo (ascorbic acid) on the platelet
count in patients in the acute phase of onyalai. Onyalai is an
acquired form of chronic immune thrombocytopenia which
occurs mainly in the Black population of southern Africa. 1,2
Many patients experience recurrent episodes of severe bleeding
heralded by the appearance of haemorrhagic bullae in the
mucous membranes of the mouth. Approximately 10% of
patients recorded in the literature died from haemorrhagic
shock or cerebral haemorrhage within days of the onset of
symptoms.2
Treatment with corticosteroids at a dose of 2 mg/kg/d did
not cause a rise in the platelet count in the fust days after the
onset of symptoms. 2,3 Ascorbic acid deficiency does not play a
role in the disease. 4 Cerebral haemorrhage may occur despite
transfusion with fresh blood.2 A splenectomy performed while
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the patient is in the acute phase of onyalai may cause a quick
rise in the platelet count, but will not always prevent future
recurrences and death. 5 The intravenous administration of
very high doses of gammaglobulin in patients with idiopathic
thrombocytopenic purpura (ITP) may cause a transient rise in
the platelet count.6-8 The infusion of fresh human plasma
containing one-tenth of the quantity of gammaglobulin used
by Imbach el al. 6 caused a rise in the circulating platelet count
in a number of adults with ITP.9
Patients and methods
Forty-two patients with onyalai who presented at Rundu State
Hospital in Kavango, SWAlNarnibia, between December 1982
and September 1983 were sequentiaIly allocated to receive one
of the following treatment schedules after informed consent
was obtained: schedule A - oral prednisolone 3 mg/kg/d ad-
ministered in three divided doses for a period of 7 days,
followed by the intramuscular injection of 40 ID corticotrophin
(Acthar Gel; Armour (Berk)); schedule B - gammaglobulin
(Gamma Veinine; Hoechst) 100 mg/kg administered intra-
venously in a saline drip on day 1 and day 2 after admission;
schedule C - oral ascorbic acid 1000 mg 3 times a day for 7
days. All the patients were observed in hospital for a minimum
period of 21 days. A blood transfusion was administered
whenever the haemoglobin level dropped below 10 g/dl.
The criteria for the diagnosis of onyalai were the presence of
haemorrhagic bullae in the buccal cavity, no clinical signs of
any other disease, platelet count < 50 x 109/1 and the absence
of abnormal cells on the peripheral blood fum.
Venous blood was obtained on admission and on days 8, 15
and 22 and tested with a Coulter Counter Model DN and a
Coulter Thrombocounter C. Giemsa stains of the peripheral
blood and a thick smear were examined for abnormal cells and
malaria parasites. The urine of every patient was tested for the
presence of protein and blood, and examined for bilharzia.
All the patients had haemorrhagic bullae. The presence of
petechiae, ecchymoses, epistaxis, melaena, haematemesis, uro-
genital bleeding and the total duration of haemorrhage in days
were recorded for each patient.
Results
The distribution of sex, age and weight in the three groups is
presented in Table I. The clinical findings on admission to
hospital are presented in Table 11. The urine of 3 patients
with haematuria contained ova of Schistosoma haematobium.
A history of a previous anack of onyalai was obtained in 6
patients in group A, 5 patients in group B and 3 patients in
group C. The mean duration of bleeding was 8,8 days (range
2 - 31 days) for group A, 6,2 days (range 1 - 19 days) for group
B and 5,1 days (range 1 - 10 days) for group C. A blood
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TABLE I. ONYALAI TREATMENT GROUPS - SEX, AGE AND
WEIGHT DISTRIBUTION
Schedule
A B C
Male: female 7:7 7:7 7:7
Mean age (yrs) 30,2 21,6 19,6
Range 2 - 70 2·67 1 - 55
Mean weight (kg) 46,1 41,6 35,8
Range 13 -70 13 - 80 11 - 59
TABLE 11. CLINICAL DATA ON ADMISSION
Schedule
A B C Total
Haemorrhagic bullae 14 14 14 42
Petechiae 9 9 10 28
Epistaxis 7 7 5 19
Ecchymoses 4 2 2 8
Urogenital bleeding 2 4 0 6
Haematemesis/
melaena 0 3 2 5
variate multisample median test. No significant differences
between the three groups were present (haemoglobin concen-
tration P> 0,25, platelet count P > 0,05).
A patient in group A died on day 15 from haemorrhagic
shock. A patient in group B absconded on day IS and the
blood specimen collected on day 22 from a patient in group C
was lost.
Discussion
The short-term rise in the platelet count in two groups of 14
patients treated with prednisolone 3 mg/kg/d for 1 \Yeek or
intravenous garnmaglobulin 100 mglkg on 2 successiv.e days
did not differ statistically from each other or from that in
another group of 14 patients who had been treate~ with
ascorbic acid I 000 mg 3 times daily for I week as a placebo.
Forrunately, cerebral haemorrhage was not encountered among
this series of 42 patients. The clinical and laboratory findings
were in keeping with those reported by others.2-4 The very low
mortality rate in this series (which might have been nil if the
patient who died had been resuscitated more actively) could
only be explained by the beneficial effects of hospitalization
during the acute haemorrhagic phase of onyalai and the early
correction of blood loss.
TABLE Ill. MEAN HAEMOGLOBIN AND PLATELET VALUES
(INTERQUARTILE RANGES GIVEN IN BRACKETS)
Schedule
A B c
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Haemoglobin concentration
(g/dl) on day 1 10,7 (3,8) 10,6 (8,2) 10,1 (1,9)
Platelet count (x 109 /1)
Day 1 35 (13) 33 (17) 36 (11)
Day 8 138 (175) 144 (206) 101 (107)
Day 15 138 (116) 193 (247) 203 (207)
Day 22 134 (101) 175 (211) 176 (155)
transfusion was necessary in 5 patients in group A, 7 patients
in group Band 4 patients in group C. The mean haemoglobin
values on day I (admission) and the platelet counts on days 1,
8, 15 and 22 are presented in Table Ill.
The males and females in each group were comparable in
respect of platelet and haemoglobin observations according to
the Generalized Friedman Test. The data on haemoglobin con-
centration and platelet count for the three groups for the
whole period of observation were then subjected to the multi-
REFERE TCES
I. Brink S, Hesseling PB, Amadhila S, Visser HS. Platelet antibodies in
immune thrombocytopenic purpura and onyalai. S Afr Med J 1981; 59:
855-858.
2. Hesseling PR. Onyalai, an epidemiological srudy (M.D. thesis), University
of Stellenbosch, 1983.
3. Barss P. Diagnosis and management of onyalai. Trop Doe! 1976; 6: 50-53.
4. Gear ]. Onyalai: a form of purpura occurring in tropical Africa: report of
cases occurring in South Africa. S Afr Med] 1938; 12: 636-637.
5. Hesseling PR, Oosthuysen E, Pretorius L, Swan A, Steynberg]. Splenectomy
in onyalai. S Air Med] 1984; 66: 580-582.
6. Imbach P, d'Apuzzo V, Hirt A er al. High-dose intravenous gammaglobulin
for idiopathic thrombocytopenic purpura in childhood. Lancer 1981; i:
1228-1231.
7. Abe T, Matsuba J, Kawasugi K, Yoshimura Y, Kinoshita T, Kazama M.
Oinicai effect of intravenous immunoglobulin on chronic idiopathic thrombo-
cytopenic purpura. Blu! 1983; 47: 69-75.
8. Bussel JB, Schulman I, Hilgarrner MW, Barandun S. Intravenous use of
gammaglobulin in the treatment of chronic immune thrombocytopenic
purpura as a means to defer splenectomy.] Pediatr 1983; 10: 651-654.
9. Lehoczky D, Kelemen E. The effect of fresh human plasma infusion on the
Circulating platelet count in adults with idiopathic thrombocytopenia. N
Engl] Med 1982; 307: 1150.
